The Latest Breaking News from FDA

HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami. The analyst is bullish on: Significant potential for NRX-101 for…

Discreet and available by mail, abortion-inducing pills could make conservative abortion bans challenging to enforce.

Senators asked for an investigation since the "sweet, chocolaty taste may encourage consumers to eat well over a recommended quantity of melatonin."

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Q: Why am I seeing brands of baby formula I’ve never heard of, and are they safe?

The Biden administration says it’s taking steps to increase access to medication abortion in response to the Supreme Court decision to reverse Roe v. Wade, but some of the administration’s own policies stand in the way of people trying to get the drug.

In a highly anticipated but not unexpected 6-3 decision, the Supreme Court ruled on June 30, 2022, that the Obama administration’s Clean Power Plan exceeded the U.S. Environmental Protection Agency’s authority under the Clean Air Act.

Beginning July 1, the Oregon Liquor and Cannabis Commission (OLCC) will be restricting the sale of some artificially derived synthetic cannabinoids in the state, reported the Oregonian.

A little competition can greatly benefit patients. Shareholders may have a more difficult path to navigate.